Phase I/II trial of single-agent sphigosomal vincristine in patients with recurrent or refractory acute lymphoblastic leukaemia.

Trial Profile

Phase I/II trial of single-agent sphigosomal vincristine in patients with recurrent or refractory acute lymphoblastic leukaemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs Vincristine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Sponsors Talon Therapeutics
  • Most Recent Events

    • 05 Dec 2012 Results from this trial will be included in a pooled analysis to be presented at the American Society of Hematology Annual Meeting (ASH-2012) according to a Talon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top